Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5280561
Max Phase: Preclinical
Molecular Formula: C22H21F4N5
Molecular Weight: 431.44
Associated Items:
ID: ALA5280561
Max Phase: Preclinical
Molecular Formula: C22H21F4N5
Molecular Weight: 431.44
Associated Items:
Canonical SMILES: CN1CCN(c2ccc(Nc3nccc(-c4ccc(F)cc4)n3)cc2C(F)(F)F)CC1
Standard InChI: InChI=1S/C22H21F4N5/c1-30-10-12-31(13-11-30)20-7-6-17(14-18(20)22(24,25)26)28-21-27-9-8-19(29-21)15-2-4-16(23)5-3-15/h2-9,14H,10-13H2,1H3,(H,27,28,29)
Standard InChI Key: PAHHDKVUHLNVHT-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 431.44 | Molecular Weight (Monoisotopic): 431.1733 | AlogP: 4.80 | #Rotatable Bonds: 4 |
Polar Surface Area: 44.29 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.66 | CX LogP: 5.18 | CX LogD: 4.73 |
Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.60 | Np Likeness Score: -1.69 |
1. Wlodarchak N, Feltenberger JB, Ye Z, Beczkiewicz J, Procknow R, Yan G, King TM, Golden JE, Striker R.. (2021) Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry., 12 (2.0): [PMID:35035774] [10.1021/acsmedchemlett.0c00580] |
Source(1):